Moteur de recherche d’entreprises européennes
Financement de l’UE (240 530 €) : Développement de lymphocytes T porteurs de nanoparticules sensibles aux stimuli dans la lutte contre le cancer Hor 08/05/2018 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Développement de lymphocytes T porteurs de nanoparticules sensibles aux stimuli dans la lutte contre le cancer
The cancer burden represents an overarching health problem and it is essential that EU institutions develop the next generation of diagnostics that overcome the inadequacy of current imaging strategies. Nanomedicine, defined as the use of nanotechnologies in medicine, offers extraordinary opportunities to address these unmet medical needs. The proposed research project endeavours to find effective anticancer diagnostics through the development of smart cellular nano-machines. The design will integrate white blood cells (concretely, tumour-targeted T lymphocytes) as living carriers of stimuli-responsive drug-loaded NPs. The tumour-homing T cells will facilitate NP accumulation in tumours until an internal/external stimulus triggers NP-release. The NPs will also possess imaging capabilities to visualize and monitor the injected formulations and confirm that the designed NPs target cancer cells in vivo. This approach aims to achieve highly versatile, selective and effective nanomedicine products that combine imaging and therapy for different types of cancer (theranostics). The strategy will provide anticancer materials compatible with industrial processes and personalized medicine. Thus, I believe the results arising from this work will place EU institutions in an unbeatable position to capitalize on the next generation of diagnostics, not only to boost the competitiveness of our industries but also to make positive changes in the lives of our citizens.
| Sloan-Kettering Institute for Cancer Research Corporation | ? |
| Katholieke Universiteit Leuven | 240 530 € |
https://cordis.europa.eu/project/id/796672
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Sloan-Kettering Institute for Cancer Research CORPORATION, City of New York, États-Unis.